Notice of allowance for patent grant in Japan
Poolbeg Pharma PLC (AIM:PLOB) Immunomodulator I Patent Opposition Withdrawal
An important step in the continued protection of Poolbeg’s patent family
Poolbeg Pharma PLC (AIM:POLB) Interim results for the six months to 30 June 2023
Significant progress made and well positioned for future growth
Poolbeg Pharma PLC (AIM:POLB) AI led programme identifies influenza drug targets
Successful Artificial Intelligence led programme identifies multiple influenza drug targets
Poolbeg Pharma PLC (AIM:POLB) Oral Vaccine Programme Moves Forward
Next-Generation Oral Vaccine Programme Advancing Through Non-Dilutive Funding
Poolbeg Pharma PLC – Board Appointment
Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a leading biopharmaceutical company focusing on infectious and prevalent diseases with a high unmet medical need, announces the appointment of Brendan Buckley as
Poolbeg Pharma PLC (AIM:POLB) Annual Report & AGM Notice
Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a leading biopharmaceutical company focusing on infectious and prevalent diseases with a high unmet medical need, confirms that the Company’s
Poolbeg Pharma PLC (AIM:POLB) Results for the year ended 31 December 2022
Significant milestones reached, well capitalised and positioned for future growth
Poolbeg Pharma PLC (AIM:POLB) POLB 001 patent portfolio strengthened
POLB 001 patent portfolio strengthened through granting of US patent
Poolbeg Pharma Plc (AIM:POLB) Positive Results from POLB 001 LPS Human Challenge Trial
Strong potential for POLB 001 to be a blockbuster treatment for severe influenza
Poolbeg Pharma PLC (AIM:POLB) Strategic expansion of POLB 001 into oncology
Complements strong initial data from LPS challenge trial and is in line with stated objective at IPO to expand POLB 001 to additional indications.